XOMA receives $4.9M commercial payment from Genentech for VABYSMO H1 2023 sales

XOMA Royalty Corp

Received $4.9 million from Genentech (Roche) for VABYSMO net sales in first six months of 2023.
Payment reflects 0.5% royalty stream on VABYSMO sales in certain regions for ten years from first commercial sale.
XOMA acquired this royalty interest through an October 2021 purchase agreement with Affitech Research AS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.